Skip to content
OpenCapital
Get started

Tango Therapeutics TNGX EV / sales

EV / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
3.3×-0.1×
Amgen logo
AmgenAMGN
6.6×+0.1×
Gilead Sciences logo
Gilead SciencesGILD
6.3×+0.9×
Exelixis logo
ExelixisEXEL
4.7×+0.3×
CG Oncology logo
CG OncologyCGON
1,121.8×-1,637×
Lantheus Holdings logo
Lantheus HoldingsLNTH
3.3×-0.9×

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

enterprise value/total revenue=50.1×

Based on the most recent quarter.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's EV / sales?
Tango Therapeutics (TNGX) reported EV / sales of 50.1× in Q1 2026.
How has Tango Therapeutics's EV / sales changed year-over-year?
Tango Therapeutics's EV / sales increased by 1556.9% year-over-year, from 3× to 50.1×.
What is the long-term trend for Tango Therapeutics's EV / sales?
Over 4 years (2021 to 2025), Tango Therapeutics's EV / sales has grown at a -5.2% compound annual growth rate (CAGR), from 22.1× to 17.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.